Hemostemix Announces First Patient Treated in Stem Cell Trial for Critical Limb Ischemia

May 3, 2018

Hemostemix Inc. (TSX VENTURE:HEM) announced on 5/3/18 that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”).  The first patient was treated at the Vancouver Coastal Health Research Institute (“VCHRI”), a world leader in translational health research for new therapies, led by the principal investigator, Dr. York N. Hsiang, MB ChB MHSc FRCSC.

The ongoing Phase II clinical trial investigates the safety and efficacy of the Company’s lead product, ACP-01.  The Company’s patented process results in producing specific stem cells that have the ability to support the generation of new blood vessels to combat the life-threatening complications of CLI. The stem cells are raised and expanded from the patient’s blood and then re-injected into the diseased tissue.  The results of the current clinical trial will determine whether the curative effects seen in Phase I trials of ACP-01 will be equally strong in a larger and more varied patient group.

Critical limb ischemia (CLI) is characterized by chronic, inadequate blood flow to limbs, resulting in tissue loss and gangrene. Currently, no treatment exists for the most critical patients.


CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.